Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Tirzepatide (5mg 10mg 15mg 20mg 30mg) CagriSema vs. Tirzepatide: Which One MELTS Fat Faster? Dr. Dan Obesity Expert GLP 1 Weight Loss Drugs: How Semaglutide & Tirzepatide Redefine Obesity Care